Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Regulatory Material +

Quantum Biopharma wins market manipulation lawsuit

By The Northwire Desk — AI Analysis Apr 02, 2026 · 18:11 QNTM · 5.6 Quantum Biopharma Ltd
QNTM · Price

Executive Summary

  • Quantum Biopharma Ltd. secured a major legal victory as the U.S. District Court for the Southern District of New York denied CIBC World Markets and RBC Dominion Securities’ joint motion to dismiss its lawsuit alleging illegal market manipulation.
  • The court’s ruling allows Quantum Biopharma’s claims—covering alleged spoofing activities from Jan 1 2020 through Aug 15 2024—to proceed, potentially exposing the defendants to significant liability.
  • The outcome is material‑positive for Quantum Biopharma, removing a major legal hurdle and supporting its position in ongoing securities‑law disputes.

Key Details

  • Court Decision: The court “largely ruled against” the defendants’ motion to dismiss, meaning the lawsuit will continue on the merits.
  • Defendants: CIBC World Markets and RBC Dominion Securities (jointly).
  • Allegations: Between Jan 1 2020 and Aug 15 2024, the defendants and/or their customers allegedly used spoofing techniques to manipulate Quantum Biopharma’s share price.
  • Legal Basis: Claims allege violations of Section 10(b) and Rule 10b‑5(a) & (c), as well as Section 9(a) of the Securities Exchange Act of 1934.
  • Potential Exposure: The lawsuit seeks damages up to USD $700,000,000 for alleged market manipulation.
  • Impact on Quantum Biopharma: Removal of the dismissal barrier enhances the company’s ability to pursue full recovery and may deter future manipulative activity against its securities.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Quantum Biopharma Ltd

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other